NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral

2026-07-24 Recommendation based on NEXUS data; Minoryx and Neuraxpharm expect European Commission approval by the end of this quarter Barcelona, Spain and Düsseldorf, Germany – 24 July, 2026 – Minoryx Therapeutics and Neuraxpharm Group, announce that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation approval under…

Aura Biosciences to Participate in Upcoming Investor Conference

September 2, 2026PDF Version BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that Natalie Holles, CEO and President, will participate in the following upcoming investor conference: Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026.Fireside Chat at 2:35…

Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 1, 2026PDF Version BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Erica Kratz, Ph.D., Aura’s…

Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 11, 2026PDF Version Phase 3 CoMpass trial fully enrolled with 108 patients, exceeding enrollment target; on track for topline data in 2H 2027 Strategic operating plan refined to focus on development of bel-sar in ocular oncology Interim NMIBC data reinforce bel-sar’s potential for durable efficacy and favorable safety profile; NMIBC program being strategically deprioritized…

Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors

BOSTON, July 08, 2026 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Jeremy Bender, Ph.D., M.B.A., to its Board of Directors. “I am thrilled to welcome Jeremy to our Board of Directors and excited to be working alongside him again,”…

Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that its Board of Directors has appointed Natalie Holles as Chief Executive Officer and President and member of the Board of Directors, effective April 30, 2026. Ms. Holles succeeds Elisabet de los Pinos, Ph.D., the Company’s founder,…

Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of…

Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consisting of (i) 39,591,000 shares of its common stock and (ii) in lieu of common stock to certain investors, pre-funded warrants…

Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

BOSTON, May 05, 2026 (GLOBE NEWSWIRE)  Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the closing of its previously announced underwritten public offering. In the offering, Aura sold (i) 46,099,650 shares of common stock, which includes 6,508,650 shares sold upon exercise in…

Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights

BOSTON, May 11, 2026 (GLOBE NEWSWIRE) Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights. “We are entering a pivotal period for Aura as we advance our Phase 3 CoMpass trial…